Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo
Brief Summary: The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid tumor.


Options:
A: Arm Label: Arm I (octreotide acetate and bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Drug: Octreotide Acetate | Arm Label: Arm II (octreotide acetate and recombinant interferon alfa-2b); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Octreotide Acetate, Biological: Recombinant Interferon Alfa-2b | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm I (octreotide acetate and bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (octreotide acetate and bevacizumab), Arm II (octreotide acetate and recombinant interferon alfa-2b) | Intervention Type: DRUG; Name: Octreotide Acetate; Assigned to Arm(s): Arm I (octreotide acetate and bevacizumab), Arm II (octreotide acetate and recombinant interferon alfa-2b) | Intervention Type: BIOLOGICAL; Name: Recombinant Interferon Alfa-2b; Assigned to Arm(s): Arm II (octreotide acetate and recombinant interferon alfa-2b)
B: Arm Label: lanreotide; Type: EXPERIMENTAL; Interventions: Drug: lanreotide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: lanreotide; Assigned to Arm(s): lanreotide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Octreotide+ Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Octreotide, Drug: Everolimus | Arm Label: Octreotide+ Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Octreotide, Drug: Placebo | Intervention Type: DRUG; Name: Octreotide; Assigned to Arm(s): Octreotide+ Everolimus, Octreotide+ Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Octreotide+ Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Octreotide+ Everolimus
D: Arm Label: 177Lu-DOTA-EB-TATE 1; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-EB-TATE 1 | Arm Label: 177Lu-DOTA-EB-TATE 2; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-EB-TATE 2 | Arm Label: 177Lu-DOTA-EB-TATE 3; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-EB-TATE 3 | Arm Label: 177Lu-DOTA-TATE; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-TATE | Arm Label: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine); Type: EXPERIMENTAL; Interventions: Drug: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine) | Arm Label: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine); Type: EXPERIMENTAL; Interventions: Drug: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine) | Intervention Type: DRUG; Name: 177Lu-DOTA-EB-TATE 1; Assigned to Arm(s): 177Lu-DOTA-EB-TATE 1 | Intervention Type: DRUG; Name: 177Lu-DOTA-TATE; Assigned to Arm(s): 177Lu-DOTA-TATE | Intervention Type: DRUG; Name: 177Lu-DOTA-EB-TATE 2; Assigned to Arm(s): 177Lu-DOTA-EB-TATE 2 | Intervention Type: DRUG; Name: 177Lu-DOTA-EB-TATE 3; Assigned to Arm(s): 177Lu-DOTA-EB-TATE 3 | Intervention Type: DRUG; Name: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine); Assigned to Arm(s): 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine) | Intervention Type: DRUG; Name: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine); Assigned to Arm(s): 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)

Answer: C